{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:33:32Z","timestamp":1791419612242,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Research Fund of Istanbul University","award":["ONAP-4024"],"award-info":[{"award-number":["ONAP-4024"]}]},{"name":"Research Fund of Istanbul University","award":["ONAP-28651"],"award-info":[{"award-number":["ONAP-28651"]}]},{"name":"Research Fund of Istanbul University","award":["ONAP-21712"],"award-info":[{"award-number":["ONAP-21712"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jneuroim.2015.04.014","type":"journal-article","created":{"date-parts":[[2015,4,26]],"date-time":"2015-04-26T01:41:39Z","timestamp":1430012499000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"special_numbering":"C","title":["The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease"],"prefix":"10.1016","volume":"283","author":[{"given":"Erdin\u00e7","family":"Dursun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Gezen-Ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha\u015fmet","family":"Hana\u011fas\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u015far","family":"Bilgi\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebba","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Ertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem L.","family":"Atasoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Alayl\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr Selin","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"\u00d6nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fclya","family":"Apayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcne\u015f","family":"K\u0131z\u0131ltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgut","family":"Ulutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"G\u00fcrvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Y\u0131lmazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.04.014_bb0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02815005","article-title":"Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease","volume":"29","author":"Alvarez","year":"1996","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0304-3940(98)00136-0","article-title":"Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease","volume":"244","author":"Angelis","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0015","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/00207450701392068","article-title":"Cytokines in Alzheimer's disease and vascular dementia","volume":"118","author":"Angelopoulos","year":"2008","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.imlet.2008.02.002","article-title":"Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease","volume":"117","author":"Bermejo","year":"2008","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0025","doi-asserted-by":"crossref","first-page":"e29868","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease","volume":"7","author":"Bjorkqvist","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","article-title":"Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients","volume":"202","author":"Blum-Degen","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","article-title":"Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism","volume":"441","author":"Brodacki","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.jneuroim.2015.04.014_bb0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3988\/jcn.2008.4.2.84","article-title":"Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology","volume":"4","author":"Choi","year":"2008","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0050","first-page":"55","article-title":"Study of interleukin-6 production in Alzheimer's disease","volume":"49","author":"Cojocaru","year":"2011","journal-title":"Rom. J. Intern. Med."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10522-011-9335-6","article-title":"Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration","volume":"12","author":"Corsi","year":"2011","journal-title":"Biogerontology"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/prca.200780101","article-title":"Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma","volume":"2","author":"Cutler","year":"2008","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0065","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0047-6374(01)00313-X","article-title":"Inflammatory markers in Alzheimer's disease and multi-infarct dementia","volume":"122","author":"De Luigi","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0070","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.parkreldis.2008.05.014","article-title":"Serum inflammatory biomarkers in Parkinson's disease","volume":"15","author":"Dufek","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000255051","article-title":"Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment","volume":"28","author":"Forlenza","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0301-0082(97)00021-X","article-title":"Interleukin-6 (IL-6)\u2014a molecule with both beneficial and destructive potentials","volume":"52","author":"Gadient","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JAD-130497","article-title":"BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment","volume":"37","author":"Gezen-Ak","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000329568","article-title":"Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias","volume":"9","author":"Helmy","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0100","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s11064-009-9921-z","article-title":"Interleukin-6 serum levels in patients with Parkinson's disease","volume":"34","author":"Hofmann","year":"2009","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0404.1997.tb00275.x","article-title":"Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease","volume":"96","author":"Kalman","year":"1997","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0110","first-page":"170","article-title":"Raised serum proinflammatory cytokines in Alzheimer's disease with depression","volume":"5","author":"Khemka","year":"2014","journal-title":"Aging Dis."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cyto.2012.07.030","article-title":"Inflammatory cytokines and NT-proCNP in Parkinson's disease patients","volume":"60","author":"Koziorowski","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002093-199809000-00016","volume":"12","author":"Lanzrein","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.imlet.2008.09.004","article-title":"Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment","volume":"121","author":"Lee","year":"2008","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00002093-199509020-00009","article-title":"Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease","volume":"9","author":"Licastro","year":"1995","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-5728(99)00226-X","article-title":"Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?","volume":"103","author":"Licastro","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0140","doi-asserted-by":"crossref","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","article-title":"Non-motor symptoms in patients with Parkinson's disease \u2014 correlations with inflammatory cytokines in serum","volume":"7","author":"Lindqvist","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neurobiolaging.2009.03.011","article-title":"Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease","volume":"32","author":"Marksteiner","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","article-title":"Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study","volume":"50","author":"Marksteiner","year":"2014","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0155","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0197-4580(01)00289-5","article-title":"Inflammation, autotoxicity and Alzheimer disease","volume":"22","author":"McGeer","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0404.1998.tb01736.x","article-title":"Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease","volume":"98","author":"Muller","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1155\/2007\/432190","article-title":"The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline","volume":"18","author":"Ozturk","year":"2007","journal-title":"Behav. Neurol."},{"issue":"Suppl. 10","key":"10.1016\/j.jneuroim.2015.04.014_bb0170","first-page":"43","article-title":"The role of IL-6 in mediating the anti-inflammatory effects of exercise","volume":"57","author":"Petersen","year":"2006","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0197-4580(94)90026-4","article-title":"Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease","volume":"15","author":"Pirttila","year":"1994","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0180","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s11064-012-0708-2","article-title":"Neuroinflammation and synaptic loss","volume":"37","author":"Rao","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0185","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0190","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jcp.24266","article-title":"Alpha-2-macroglobulin: a physiological guardian","volume":"228","author":"Rehman","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0195","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpsychires.2004.12.005","article-title":"Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?","volume":"39","author":"Richartz","year":"2005","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0165-5728(95)00134-4","article-title":"Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain","volume":"63","author":"Ringheim","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0205","first-page":"129","article-title":"Alpha-2-macroglobulin","volume":"16","author":"Roberts","year":"1985","journal-title":"J. Med."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2009.10.062","article-title":"Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance","volume":"468","author":"Scalzo","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1020568013953","article-title":"Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia","volume":"19","author":"Tarkowski","year":"1999","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0220","doi-asserted-by":"crossref","first-page":"17714","DOI":"10.1523\/JNEUROSCI.1253-12.2012","article-title":"Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1beta via p38 mitogen-activated protein kinase","volume":"32","author":"Tong","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0225","first-page":"cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0230","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00189310","article-title":"Serum alpha(1)-antitrypsin and alpha(2)-macroglobulin in Alzheimer's and Binswanger's-disease","volume":"72","author":"Wetterling","year":"1994","journal-title":"Clin. Investig."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0235","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1021\/bi00203a024","article-title":"Neurotrophin binding to human alpha 2-macroglobulin under apparent equilibrium conditions","volume":"33","author":"Wolf","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0240","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00406-006-0652-8","article-title":"Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia","volume":"256","author":"Yasutake","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/gps.1674","article-title":"High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia","volume":"22","author":"Zuliani","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.04.014_bb0250","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jns.2008.05.020","article-title":"Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia","volume":"272","author":"Zuliani","year":"2008","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:25:06Z","timestamp":1759047906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":50,"alternative-id":["S0165572815001101"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.04.014","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}